NovoCure Posts Record $193M Quarterly Revenue
Device suppliers serving oncology practices should note how a competing drug is slowing prescribing of one product while Japan adds volume.
Updated on Nov. 2, 2026 in Healthcare
NovoCure reported record third-quarter 2026 net revenue of $193 million on October 29, 2026, and raised its full-year revenue guidance to $736 million to $743 million. Companies selling cancer treatment devices and their clinical partners are watching how competing therapies affect prescribing.
Why it matters
Slowed prescribing for Optune Pax in pancreatic cancer was attributed to the introduction of the competing drug diraxonrasib, which overburdened clinical practices with insurance appeals and side-effect management. Growth in Japan and the expansion of Optune Gio signal that revenue is shifting toward other markets and products.
NovoCure's third-quarter 2026 net revenue reached a record $193 million, with Optune Gio net revenue rising 16% year over year to deliver $16 million in adjusted EBITDA. Japan commercial expansion for Optune Lua contributed $4 million in third-quarter net revenue, and full-year guidance was revised to $736 million to $743 million.
The players
NovoCure
NovoCure is a medical device company that markets Tumor Treating Fields therapies, including Optune Gio, Optune Lua and Optune Pax, to treat cancer.
Diraxonrasib
Diraxonrasib is a competing cancer drug that was introduced in the U.S. market and has affected prescribing of NovoCure's Optune Pax for pancreatic cancer.
The details
Optune Pax is used in pancreatic cancer, and its prescribing growth slowed after diraxonrasib entered the U.S. market. Clinical practices became overburdened with insurance appeals and side-effect management tied to the competing drug, which also limits NovoCure's ability to access practices to detail Optune Pax. Monthly reimbursement pricing for Optune Lua in Japan matches established global levels, supporting the Japan expansion.
Timeline
October 29, 2026: NovoCure held its third-quarter 2026 earnings call and reported the record $193 million in quarterly net revenue.
This year (2026): NovoCure expects to achieve adjusted EBITDA positivity.
Heading into 2027: Growth expectations depend on upcoming regulatory decisions and international launches.
Market Landscape
NovoCure's Tumor Treating Fields platform is being tested by a newly introduced competitor in pancreatic cancer, which slowed prescribing growth for Optune Pax in the U.S. market. Growth is instead coming from Optune Gio and from Japan, where Optune Lua monthly reimbursement pricing matches established global levels.
Operators in healthcare supply and oncology services should watch how competing therapies change clinical workloads, since insurance appeals and side-effect management can slow adoption of an established treatment. Companies selling into Japan's reimbursement system may find that matching global pricing levels supports new market entry.
The takeaway
Track the timing of NovoCure's regulatory decisions and any update on achieving adjusted EBITDA positivity this year, since both will shape the company's 2027 outlook. Operators in medical device supply should watch how a new competing therapy shifts clinical workload and sales access, because the Optune Pax slowdown shows that crowded treatment pathways can limit a product's reach even when the product remains established.
What happens next
NovoCure has said it expects to achieve adjusted EBITDA positivity this year and will update on profitability progress and objectives in the coming months, with growth expectations tied to upcoming regulatory decisions and international launches heading into 2027.
Further reading
For broader context on how device makers and drugmakers compete for oncology prescriptions, explore our Healthcare coverage.
Source note: This article includes information reported by The Motley Fool.
